FDA Submits Information Collection for Review Under Paperwork Reduction Act

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, as required by the Paperwork Reduction Act of 1995, in order to obtain a waiver of the in vivo demonstration of bioequivalence for animal drugs in soluble powder oral dosage form products and type A medicated articles.